Download Files:
GSK-626616
$57 – $1,050
Products Details
Product Description
– GSK-626616 is a potent, orally bioavailable inhibitor of DYRK3 (IC50=0.7 nM). GSK-626616 inhibits other members of the DYRK family (e.g., DYRK1A and DYRK2) with similar potency, which is a potential therapy for the treatment of anemia[1].
Web ID
– HY-105309
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– COVID-19-immunoregulation
Molecular Formula
– C18H10Cl2N4OS
References
– [1]Connie L. Erickson-Miller, et al. GSK626616: A DYRK3 Inhibitor as a Potential New Therapy for the Treatment of Anemia. Blood 2007 110:510;|[2]Wippich F, et al. Dual specificity kinase DYRK3 couples stress granule condensation/dissolution to mTORC1 signaling. Cell. 2013;152(4):791-805.
CAS Number
– 1025821-33-3
Molecular Weight
– 401.27
Compound Purity
– 99.68
SMILES
– O=C1N=C(NC2=C(Cl)C=CC=C2Cl)S/C1=CC3=CC=C4N=CC=NC4=C3
Clinical Information
– No Development Reported
Research Area
– Cardiovascular Disease
Solubility
– DMSO : 50 mg/mL (ultrasonic)
Target
– DYRK
Isoform
– DYRK1;DYRK2;DYRK3
Pathway
– Protein Tyrosine Kinase/RTK
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
